Morgan Jones, M;
Chataway, J;
(2021)
The Structural Genomics Consortium: successful organisational technology experiment or new institutional infrastructure for health research?
Technology Analysis and Strategic Management
, 33
(3)
pp. 296-306.
10.1080/09537325.2021.1882673.
Preview |
Text
The Structural Genomics Consortium successful organisational technology experiment or new institutional infrastructure for health research.pdf - Published Version Download (1MB) | Preview |
Abstract
In a sector characterised by patenting, direct appropriations and returns from investment, the Structural Genomics Consortium (SGC) constitutes a radically different public-private and entirely open access approach to pre-competitive research. This paper discusses the significance of findings from the first independent review of the SGC. We argue that the SGC offers a shared knowledge resource for drug discovery which is distinctive from other types of knowledge production and, as such, provides a knowledge infrastructure for the wider scientific community. We distinguish three ways in which this infrastructure functions as a model for investing in, extracting value from, and generating knowledge for the field. Our analysis suggests there is a future for open science models such as the SGC in health research and innovation, but that such models raise a set of challenges over the role of different public and private institutional actors and the way in which value is extracted.
| Type: | Article |
|---|---|
| Title: | The Structural Genomics Consortium: successful organisational technology experiment or new institutional infrastructure for health research? |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1080/09537325.2021.1882673 |
| Publisher version: | https://doi.org/10.1080/09537325.2021.1882673 |
| Language: | English |
| Additional information: | © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http:// creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
| Keywords: | Pharmaceutical innovation, open science, public-private partnerships, IPR |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > UCL BEAMS UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > STEaPP |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10124377 |
Archive Staff Only
 |
View Item |
